Transthyretin Amyloid Cardiomyopathy

is a rare, progressive, highly underdiagnosed, debilitating, and fatal disease that affects the heart. It is characterized by the buildup of amyloid fibrils composed of abnormal deposits of misfolded protein aggregates.
ATTR-CM is significantly under or misdiagnosed, making it difficult to characterize worldwide prevalence.

Education is important to help recognize symptoms and improve diagnosis.
There are **two sub-types** of transthyretin amyloid cardiomyopathy.

**Hereditary:**  
(also known as variant) inherited & caused by a genetic mutation.

**Wild type:**  
is believed to account for the majority of patients and is associated with aging.
At Pfizer, we have a longstanding heritage in bringing cardiovascular medicines to patients who need them. As part of our commitment to advancing breakthroughs that transform patients’ lives, we have drawn upon our legacy in the cardiovascular space to address the needs of people living with rare and underdiagnosed conditions, like ATTR-CM.

This World Heart Day, we pledge to strengthen our efforts to raise awareness of ATTR-CM, inviting you to be Amyloidosis Heart Heroes and help us to improve time to diagnosis of this life-threatening disease.

Paul Levesque,
Global President,
Pfizer Rare Disease
Transthyretin Amyloidosis

is a disease characterized by the abnormal buildup of amyloid deposits composed of misfolded transthyretin protein in the body’s organs and tissues; this build up is called amyloidosis.